- Home
- NVAX vs PHVS Comparison
NVAX vs PHVS Comparison
Compare NVAX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- PHVS
- Stock Information
- Founded
- NVAX 1987
- PHVS 2015
- Country
- NVAX United States
- PHVS Switzerland
- Employees
- NVAX N/A
- PHVS N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NVAX Health Care
- PHVS Health Care
- Exchange
- NVAX Nasdaq
- PHVS Nasdaq
- Market Cap
- NVAX 1.3B
- PHVS 1.3B
- IPO Year
- NVAX 1995
- PHVS 2021
- Fundamental
- Price
- NVAX $7.98
- PHVS $23.33
- Analyst Decision
- NVAX Buy
- PHVS Strong Buy
- Analyst Count
- NVAX 7
- PHVS 5
- Target Price
- NVAX $14.29
- PHVS $35.60
- AVG Volume (30 Days)
- NVAX 7.2M
- PHVS 130.6K
- Earning Date
- NVAX 11-11-2025
- PHVS 08-12-2025
- Dividend Yield
- NVAX N/A
- PHVS N/A
- EPS Growth
- NVAX N/A
- PHVS N/A
- EPS
- NVAX 2.54
- PHVS N/A
- Revenue
- NVAX $1,078,718,000.00
- PHVS N/A
- Revenue This Year
- NVAX $61.69
- PHVS N/A
- Revenue Next Year
- NVAX N/A
- PHVS N/A
- P/E Ratio
- NVAX $3.25
- PHVS N/A
- Revenue Growth
- NVAX 9.22
- PHVS N/A
- 52 Week Low
- NVAX $5.01
- PHVS $11.51
- 52 Week High
- NVAX $15.22
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- NVAX 51.06
- PHVS 55.09
- Support Level
- NVAX $7.63
- PHVS $21.50
- Resistance Level
- NVAX $8.31
- PHVS $24.83
- Average True Range (ATR)
- NVAX 0.35
- PHVS 1.43
- MACD
- NVAX -0.00
- PHVS -0.02
- Stochastic Oscillator
- NVAX 65.20
- PHVS 55.25
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.